Cargando…

Clinical outcomes and toxicity using Stereotactic Body Radiotherapy (SBRT) for advanced cholangiocarcinoma

BACKGROUND: To report single-institutional clinical outcomes and toxicity with SBRT for cholangiocarcinoma. METHODS: From March 2009 to July 2011, 10 patients with 12 unresectable primary (n = 6) or recurrent (n = 6) cholangiocarcinoma lesions underwent abdominal SBRT. Sites treated included liver (...

Descripción completa

Detalles Bibliográficos
Autores principales: Barney, Brandon M, Olivier, Kenneth R, Miller, Robert C, Haddock, Michael G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464963/
https://www.ncbi.nlm.nih.gov/pubmed/22553982
http://dx.doi.org/10.1186/1748-717X-7-67
_version_ 1782245495934025728
author Barney, Brandon M
Olivier, Kenneth R
Miller, Robert C
Haddock, Michael G
author_facet Barney, Brandon M
Olivier, Kenneth R
Miller, Robert C
Haddock, Michael G
author_sort Barney, Brandon M
collection PubMed
description BACKGROUND: To report single-institutional clinical outcomes and toxicity with SBRT for cholangiocarcinoma. METHODS: From March 2009 to July 2011, 10 patients with 12 unresectable primary (n = 6) or recurrent (n = 6) cholangiocarcinoma lesions underwent abdominal SBRT. Sites treated included liver (n = 10), abdominal lymph nodes (n = 1), and adrenal gland (n = 1). SBRT was delivered in three (n = 2) or five (n = 10) consecutive daily fractions over one week. The median prescription dose was 55 Gy (range, 45–60). Treatment response was graded by RECIST v.1.1, and toxicities were scored by CTCAE v.4.0. Data was analyzed using the Kaplan-Meier method to determine rates of local control (LC), freedom from distant progression (FFDM) and overall survival (OS). RESULTS: The median follow-up was 14 months (range, 2–26 months). LC, defined as freedom from progression within the SBRT field, was 100%, but four patients treated to intrahepatic sites experienced progression elsewhere in the liver. Estimates for FFDM at 6 and 12 months were 73% and 31%, respectively. Sites of disease relapse included liver (n = 3), liver and lymph nodes (n = 1), liver and lungs (n = 1), lymph nodes (n = 1), and mesentery (n = 1). OS estimates for the cohort at 6 and 12 months were 83% and 73%, respectively. The most common Grade ≥2 early toxicities were Grade 2 nausea and vomiting (n = 5) and gastrointestinal pain (n = 2). Late ≥2 toxicities included Grade 2 gastrointestinal pain (n = 3), Grade 3 biliary stenosis (n = 1), and Grade 5 liver failure (n = 1). CONCLUSIONS: SBRT shows promise as an effective local therapy for properly-selected patients with cholangiocarcinoma. Further follow-up is needed to better quantify the risk of late complications associated with SBRT.
format Online
Article
Text
id pubmed-3464963
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34649632012-10-06 Clinical outcomes and toxicity using Stereotactic Body Radiotherapy (SBRT) for advanced cholangiocarcinoma Barney, Brandon M Olivier, Kenneth R Miller, Robert C Haddock, Michael G Radiat Oncol Research BACKGROUND: To report single-institutional clinical outcomes and toxicity with SBRT for cholangiocarcinoma. METHODS: From March 2009 to July 2011, 10 patients with 12 unresectable primary (n = 6) or recurrent (n = 6) cholangiocarcinoma lesions underwent abdominal SBRT. Sites treated included liver (n = 10), abdominal lymph nodes (n = 1), and adrenal gland (n = 1). SBRT was delivered in three (n = 2) or five (n = 10) consecutive daily fractions over one week. The median prescription dose was 55 Gy (range, 45–60). Treatment response was graded by RECIST v.1.1, and toxicities were scored by CTCAE v.4.0. Data was analyzed using the Kaplan-Meier method to determine rates of local control (LC), freedom from distant progression (FFDM) and overall survival (OS). RESULTS: The median follow-up was 14 months (range, 2–26 months). LC, defined as freedom from progression within the SBRT field, was 100%, but four patients treated to intrahepatic sites experienced progression elsewhere in the liver. Estimates for FFDM at 6 and 12 months were 73% and 31%, respectively. Sites of disease relapse included liver (n = 3), liver and lymph nodes (n = 1), liver and lungs (n = 1), lymph nodes (n = 1), and mesentery (n = 1). OS estimates for the cohort at 6 and 12 months were 83% and 73%, respectively. The most common Grade ≥2 early toxicities were Grade 2 nausea and vomiting (n = 5) and gastrointestinal pain (n = 2). Late ≥2 toxicities included Grade 2 gastrointestinal pain (n = 3), Grade 3 biliary stenosis (n = 1), and Grade 5 liver failure (n = 1). CONCLUSIONS: SBRT shows promise as an effective local therapy for properly-selected patients with cholangiocarcinoma. Further follow-up is needed to better quantify the risk of late complications associated with SBRT. BioMed Central 2012-05-03 /pmc/articles/PMC3464963/ /pubmed/22553982 http://dx.doi.org/10.1186/1748-717X-7-67 Text en Copyright ©2012 Barney et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Barney, Brandon M
Olivier, Kenneth R
Miller, Robert C
Haddock, Michael G
Clinical outcomes and toxicity using Stereotactic Body Radiotherapy (SBRT) for advanced cholangiocarcinoma
title Clinical outcomes and toxicity using Stereotactic Body Radiotherapy (SBRT) for advanced cholangiocarcinoma
title_full Clinical outcomes and toxicity using Stereotactic Body Radiotherapy (SBRT) for advanced cholangiocarcinoma
title_fullStr Clinical outcomes and toxicity using Stereotactic Body Radiotherapy (SBRT) for advanced cholangiocarcinoma
title_full_unstemmed Clinical outcomes and toxicity using Stereotactic Body Radiotherapy (SBRT) for advanced cholangiocarcinoma
title_short Clinical outcomes and toxicity using Stereotactic Body Radiotherapy (SBRT) for advanced cholangiocarcinoma
title_sort clinical outcomes and toxicity using stereotactic body radiotherapy (sbrt) for advanced cholangiocarcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464963/
https://www.ncbi.nlm.nih.gov/pubmed/22553982
http://dx.doi.org/10.1186/1748-717X-7-67
work_keys_str_mv AT barneybrandonm clinicaloutcomesandtoxicityusingstereotacticbodyradiotherapysbrtforadvancedcholangiocarcinoma
AT olivierkennethr clinicaloutcomesandtoxicityusingstereotacticbodyradiotherapysbrtforadvancedcholangiocarcinoma
AT millerrobertc clinicaloutcomesandtoxicityusingstereotacticbodyradiotherapysbrtforadvancedcholangiocarcinoma
AT haddockmichaelg clinicaloutcomesandtoxicityusingstereotacticbodyradiotherapysbrtforadvancedcholangiocarcinoma